Literature DB >> 28192645

Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma.

Liena Zhao1, Dora Dias-Santagata1, Peter M Sadow1, William C Faquin1.   

Abstract

BACKGROUND: The noninvasive follicular variant of papillary thyroid carcinoma (PTC) has an indolent clinical behavior in comparison with other PTCs, including the invasive follicular variant of papillary thyroid carcinoma (IFVPTC). Recently, the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced to emphasize the low biological potential of these tumors. This study compares clinical, cytological, and molecular features of NIFTP and IFVPTC.
METHODS: The study consisted of 97 thyroid fine-needle aspiration biopsy (FNAB) cases with corresponding surgical pathology from the pathology archives of the Massachusetts General Hospital. The collected patient data included the following: age, sex, type of surgery, tumor size, and prior cytological diagnosis with The Bethesda System for Reporting Thyroid Cytopathology. A molecular analysis using anchored multiplex polymerase chain reaction was performed for all cases. Each case was reviewed and subclassified histologically as NIFTP or IFVPTC. Cytology slides were scored semiquantitatively for nuclear atypia. The statistical analysis was performed with the nonparametric Mann-Whitney test.
RESULTS: The 97-case cohort consisted of 50 NIFTP cases and 47 IFVPTC cases, including 18 encapsulated IFVPTC cases and 29 nonencapsulated IFVPTC cases. Differences in the type of surgery (P = .0399), molecular features (P = .0141), cytological classification (P = .0266), and nuclear scores (P = .0141) between NIFTP and IFVPTC were observed. There was overlap in the cytological classification of NIFTP and IFVPTC; however, NIFTP was more often classified as atypia of undetermined significance/follicular lesion of undetermined significance or follicular neoplasm/suspicious for follicular neoplasm in comparison with both subsets of IFVPTC. NIFTP was primarily associated with mutations in RAS, whereas an equal number of IFVPTC cases were associated with BRAFV600E or with RAS mutations.
CONCLUSIONS: Despite differences in the cytological classification and molecular profiles between NIFTP and IFVPTC, the degree of overlap makes it unlikely that most cases of NIFTP and IFVPTC can be accurately distinguished with FNAB. Cancer Cytopathol 2017;125:323-331.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  Bethesda; fine-needle aspiration (FNA); follicular variant; noninvasive; noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); papillary thyroid carcinoma; thyroid

Mesh:

Substances:

Year:  2017        PMID: 28192645     DOI: 10.1002/cncy.21839

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  24 in total

Review 1.  Molecular markers in well-differentiated thyroid cancer.

Authors:  Anil K D'Cruz; Richa Vaish; Abhishek Vaidya; Iain J Nixon; Michelle D Williams; Vincent Vander Poorten; Fernando López; Peter Angelos; Ashok R Shaha; Avi Khafif; Alena Skalova; Alessandra Rinaldo; Jennifer L Hunt; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-06       Impact factor: 2.503

2.  Metastatic Follicular Thyroid Carcinoma and the Primary Thyroid Gross Examination: Institutional Review of Cases from 1990 to 2015.

Authors:  Krzysztof Glomski; Vania Nosé; William C Faquin; Peter M Sadow
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

3.  Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?

Authors:  Bin Xu; Nada Farhat; Justine A Barletta; Yin P Hung; Dario de Biase; Gian Piero Casadei; Ayse Mine Onenerk; R Michael Tuttle; Benjamin R Roman; Nora Katabi; Vania Nosé; Peter Sadow; Giovanni Tallini; William C Faquin; Ronald Ghossein
Journal:  Endocrine       Date:  2017-12-04       Impact factor: 3.633

Review 4.  Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances.

Authors:  Ying-Hsia Chu; Peter M Sadow
Journal:  Semin Diagn Pathol       Date:  2020-06-10       Impact factor: 3.464

5.  Impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on fine-needle aspiration diagnoses of thyroid nodules.

Authors:  Li Chen; Lina Liu; Parsa Hodjat; Bing Leng
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-23

Review 6.  Noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP): a new entity.

Authors:  Elisabetta Macerola; Agnese Proietti; Fulvio Basolo
Journal:  Gland Surg       Date:  2020-01

Review 7.  Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Historical Context, Diagnosis, and Future Challenges.

Authors:  Bin Xu; Giovanni Tallini; Ronald A Ghossein
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

8.  Noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP): a 13-year retrospective review at Jordan University Hospital.

Authors:  Rajai O Zurikat; Majd Khader; Muayad I Azzam; Zaid M Zahid; Samer F Daoud; Salam F Nusirat; Nader Albsoul; Motaz A Al-Natsheh; Mousa A Al-Abbadi
Journal:  Endocrine       Date:  2020-04-22       Impact factor: 3.633

9.  Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features is Rare: A Population Based Study of Incidence.

Authors:  Rasmus H Reinke; Stine R Larsen; Jes S Mathiesen; Christian Godballe; Stefano C Londero
Journal:  Head Neck Pathol       Date:  2019-03-21

Review 10.  Non-invasive follicular thyroid neoplasm with papillary-like nuclearfeatures (NIFTP): a review and update.

Authors:  Bita Geramizadeh; Zahra Maleki
Journal:  Endocrine       Date:  2019-03-13       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.